| 영문 | fibrinogen | 한글 | 섬유소원 |
|---|---|---|---|
| 설명 | 정상인의 간의 실질세포에서 합성되어 혈장에서 얻어지는 동결건조한 무균의 단백물질로서 이 용액에 트롬빈을 가하면 수용성 섬유소로 전환되는 성질을 가지고 있다. 혈액응고에 있어서 중요한 역할을 한다. 혈액응고 인자번호 I이다. |
||
| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
|---|---|
| FDP | fibrin degradation product; fibrinogen degradation product; flexor digitorum profundus; frontodextra... |
| FgDP | fibrinogen degradation products |
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| FbDP | fibrin degradation products |
| FgDP | Fibrinogen Degradation Products |
|---|---|
| FDP | Fibrinogen-Fibrin Degradation Products |
| FDP | Fibrin-fibrinogen degradation product |
| FbDP | Fibrin Degradation Products |
| GDPs | Glucose degradation products |
| fibrin fibrinogen degradation products | <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis. Pharmacological action: antithrombins. (12 Dec 1998) |
|---|---|
| fibrin degradation products | <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot. Normal value is less than 10 mcg/ml (micrograms per millilitre). They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia. Acronym: FDP (23 Sep 2002) |
| fibrinogen | <protein> Soluble plasma protein (340 kD, 46 nm long), composed of 6 peptide chains (2 each of A_, B_ and _) and present at about 2-3 mg/ml. (12 Nov 1997) |
| fibrinogen-fibrin conversion syndrome | <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma. (05 Mar 2000) |
| degradation | <biochemistry, chemistry> The reduction of a chemical compound to one less complex, as by splitting off one or more groups. (18 Nov 1997) |
| edman degradation | A lab technique used to find out the order of amino acids in a polypeptide (chain of amino acids). It involves using the Edman reagent, phenyl isothiocyanate (PITC), to react one by one with each amino acid, in order. The technique is used in machines which automatically sequence (determine the order of subunits) polypeptides. (09 Oct 1997) |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| gene products, env | Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease. (12 Dec 1998) |
| gene products, gag | Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen. (12 Dec 1998) |
| gene products, nef | Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor. (12 Dec 1998) |
| gene products, pol | Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase. (12 Dec 1998) |
| gene products, rev | Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion. (12 Dec 1998) |
| gene products, rex | Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr. (12 Dec 1998) |
| gene products, tat | Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|